血小板功能检测指导下的抗血小板治疗降阶梯在急性冠脉综合征行经皮冠状动脉介入治疗患者中的应用(TROPICAL-ACS):一项随机、开放标签、多中心试验
TROPICAL-ACS是一项在33个欧洲中心进行的研究者发起、随机、开放标签、评估者设盲、多中心试验,纳入生物标志物阳性急性冠脉综合征且成功行PCI、计划双联抗血小板治疗12个月的患者。患者随机接受标准普拉格雷治疗12个月(对照组)或阶梯降阶方案(普拉格雷1周后氯吡格雷1周,出院后第14天起根据血小板功能检测指导的维持治疗,即指导降阶梯组)。主要终点为随机化后1年净临床获益(心血管死亡、心肌梗死、卒中或BARC 2级及以上出血),非劣效界值30%。指导降阶梯组主要终点发生95例(7%),对照组118例(9%)(非劣效P=0.0004;HR 0.81,95%CI 0.62-1.06;优效性P=0.12)。作者认为,早期抗血小板降阶梯治疗可考虑作为急性冠脉综合征行PCI患者的一种替代方案。
要点
- 指导降阶梯组主要终点(心血管死亡、心肌梗死、卒中或BARC≥2级出血)1年发生率为7%(95例),对照组为9%(118例),非劣效P=0.0004,HR 0.81(95%CI 0.62-1.06)。
- 指导降阶梯组心血管死亡、心肌梗死或卒中复合风险为3%(32例),对照组为3%(42例),非劣效P=0.0115,早期降阶梯未增加缺血复合风险。
- 指导降阶梯组BARC≥2级出血事件为5%(64例),对照组为6%(79例),HR 0.82(95%CI 0.59-1.13),P=0.23。
- 作者认为,早期抗血小板降阶梯治疗可考虑作为急性冠脉综合征行PCI患者的一种替代方案。
适用人群与场景
- 生物标志物阳性急性冠脉综合征、成功行PCI且计划双联抗血小板治疗12个月的患者(TROPICAL-ACS纳入标准)。
- 研究在33个欧洲中心进行,随机化1:1分配至指导降阶梯组(1304例)或对照组(1306例)。
诊断标准与关键阈值
- 主要终点非劣效界值为30%(非劣效假设)。
- 主要终点定义:随机化后1年净临床获益,包括心血管死亡、心肌梗死、卒中或BARC 2级及以上出血。
处置流程与药物剂量
- 对照组:普拉格雷治疗12个月。
- 指导降阶梯组:普拉格雷1周,随后氯吡格雷1周,出院后第14天起根据血小板功能检测结果给予氯吡格雷或普拉格雷维持治疗。
- 双联抗血小板治疗计划疗程为12个月。
研究设计与关键结果
- 研究类型:研究者发起、随机、开放标签、评估者设盲、多中心试验;33个欧洲中心;样本量2610例(指导降阶梯组1304例,对照组1306例);纳入生物标志物阳性急性冠脉综合征成功行PCI且计划双联抗血小板治疗12个月的患者。
- 主要终点(1年净临床获益):指导降阶梯组95例(7%)vs 对照组118例(9%);非劣效P=0.0004;HR 0.81(95%CI 0.62-1.06);优效性P=0.12。
- 心血管死亡、心肌梗死或卒中复合终点:指导降阶梯组32例(3%)vs 对照组42例(3%);非劣效P=0.0115。
- BARC 2级及以上出血:指导降阶梯组64例(5%)vs 对照组79例(6%);HR 0.82(95%CI 0.59-1.13);P=0.23。
证据类型、等级与局限
- 证据类型:随机、开放标签、评估者设盲、多中心试验(TROPICAL-ACS)。
- 非劣效假设界值为30%;主要分析为意向性治疗分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,早期抗血小板降阶梯治疗可考虑作为急性冠脉综合征行PCI患者的一种替代方案。
- 指导降阶梯方案为普拉格雷1周后氯吡格雷1周,出院后第14天起根据血小板功能检测结果选择氯吡格雷或普拉格雷维持治疗。
指南或共识出处
- TROPICAL-ACS试验(ClinicalTrials.gov注册号NCT01959451;EudraCT注册号2013-001636-22)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Current guidelines recommend potent platelet inhibition with prasugrel or ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous coronary intervention (PCI). However, the greatest anti-ischaemic benefit of potent antiplatelet drugs over the less potent clopidogrel occurs early, while most excess bleeding events arise during chronic treatment. Hence, a stage-adapted treatment with potent platelet inhibition in the acute phase and de-escalation to clopidogrel in the maintenance phase could be an alternative approach. We aimed to investigate the safety and efficacy of early de-escalation of antiplatelet treatment from prasugrel to clopidogrel guided by platelet function testing (PFT).
METHODS: In this investigator-initiated, randomised, open-label, assessor-blinded, multicentre trial (TROPICAL-ACS) done at 33 sites in Europe, patients were enrolled if they had biomarker-positive acute coronary syndrome with successful PCI and a planned duration of dual antiplatelet treatment of 12 months. Enrolled patients were randomly assigned (1:1) using an internet-based randomisation procedure with a computer-generated block randomisation with stratification across study sites to either standard treatment with prasugrel for 12 months (control group) or a step-down regimen (1 week prasugrel followed by 1 week clopidogrel and PFT-guided maintenance therapy with clopidogrel or prasugrel from day 14 after hospital discharge; guided de-escalation group). The assessors were masked to the treatment allocation. The primary endpoint was net clinical benefit (cardiovascular death, myocardial infarction, stroke or bleeding grade 2 or higher according to Bleeding Academic Research Consortium [BARC]) criteria) 1 year after randomisation (non-inferiority hypothesis; margin of 30%). Analysis was intention to treat. This study is registered with ClinicalTrials.gov, number NCT01959451, and EudraCT, 2013-001636-22.
FINDINGS: Between Dec 2, 2013, and May 20, 2016, 2610 patients were assigned to study groups; 1304 to the guided de-escalation group and 1306 to the control group. The primary endpoint occurred in 95 patients (7%) in the guided de-escalation group and in 118 patients (9%) in the control group (pnon-inferiority=0·0004; hazard ratio [HR] 0·81 [95% CI 0·62-1·06], psuperiority=0·12). Despite early de-escalation, there was no increase in the combined risk of cardiovascular death, myocardial infarction, or stroke in the de-escalation group (32 patients [3%]) versus in the control group (42 patients [3%]; pnon-inferiority=0·0115). There were 64 BARC 2 or higher bleeding events (5%) in the de-escalation group versus 79 events (6%) in the control group (HR 0·82 [95% CI 0·59-1·13]; p=0·23).
INTERPRETATION: Guided de-escalation of antiplatelet treatment was non-inferior to standard treatment with prasugrel at 1 year after PCI in terms of net clinical benefit. Our trial shows that early de-escalation of antiplatelet treatment can be considered as an alternative approach in patients with acute coronary syndrome managed with PCI.
FUNDING: Klinikum der Universität München, Roche Diagnostics, Eli Lilly, and Daiichi Sankyo.
参考来源
- Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017. PMID: 28855078. doi:10.1016/S0140-6736(17)32155-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。